An interventional study of Intracranial stent for wide-necked aneurysms in Brain Diseases, Aneurysm and Intracranial Aneurysm, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.
Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 21st largest by planned enrollment of the 49 interventional ones that give a count, is one of 20 that started in 2023, is one of 37 with no phase, reaches primary completion later than 13 of the 41 other live ones, and was the 69th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Henan Provincial People's Hospital · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 22–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 9
First in 2005; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 188 across the 49 interventional studies, 600 across the 51 observational. Of the 27 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 100 have an industry lead sponsor. The 10 most frequent:
This study is registered under MicroPort NeuroTech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort NeuroTech Co., Ltd. is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
MicroPort Scientific Corporation has 8 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
7 of the studies in Intracranial Aneurysm with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06943729Huashan HospitalClinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms | 2026-12-30 |
| NCT06364293Beijing Tiantan HospitalAn Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm | 2026-12-31 |
| NCT07089862Beijing Tiantan HospitalINdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) | 2026-12-31 |
| NCT07674004Henan Provincial People's HospitalSurface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes | 2027-02-28 |
| NCT07707076Nanfang Hospital, Southern Medical UniversityFlow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 100 studies in Intracranial Aneurysm with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial was designed as a prospective, multicentre, open, non-inferiority, randomised controlled clinical trial, with the control devices being MicroVention's LVIS Intraluminal Support Device and LVIS Jr. Intraluminal Support Device. Approximately 200 subjects with intracranial aneurysms would be enrolled for stent-assisted coiling embolisation according to the inclusion and exclusion criteria specified in this trial protocol. Subjects were evaluated by mRS preoperatively, at the time of device implantation, at the time of discharge from the hospital, at 1 month (±7 days) postoperatively, at 6 months (±30 days) postoperatively, and at 12 months (±60 days) postoperatively; subjects would underwent DSA imaging at surgery and at 6 months (±30 days) postoperatively, and MRA or DSA imaging at 12 months (±60 days) postoperatively. Unplanned follow-up of the subjects would performed when necessary, and data would be recorded to evaluate the safety and efficacy of intracranial artery stent for stent-assisted coiling embolisation for the treatment of intracranial aneurysms.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
This study's planned enrollment of 200 is above the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Browse Intracranial Aneurysm studies →MicroPort NeuroTech Co., Ltd. is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
First submitted before MicroPort NeuroTech Co., Ltd. left MicroPort Scientific Corporation.
Compared within Intracranial Aneurysm, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Microport NeuroTech Intracranial Visualized Stent
Device: Intracranial stent for wide-necked aneurysms
LVIS™ and LVIS™ Jr
Device: Intracranial stent for wide-necked aneurysms
Intracranial stent for wide-necked aneurysms
Rate of aneurysms with adequate occlusion
The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm. Adequate occlusion rate includes Class I and Class II
Time frame: 6 months
Rate of stent technical success
Technical successwas defined as the stent was successfully released at the appropriate position, and covered the aneurysm's neck completely while the parent artery remained unobstructed postoperatively.
Time frame: immediately after the procedure
Rate of aneurysms with complete occlusion
The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm. Complete occlusion rate includes Class I
Time frame: 6 months
Rate of in-stent stenosis (≥50%)
Time frame: 6 months
Rate of aneurysms with adequate occlusion
Time frame: 1 year
Rate of aneurysms with complete occlusion
Time frame: 1 year
Rate of aneurysms with retreatment
Percentage of subjects who had aneurysm recurrence and underwent a secondary suergry during follow-up
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2025, 24 months after the start.
Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 24 months is below that.
Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MicroPort NeuroTech Co., Ltd. →